The cumulative success of three pivotal trials strengthens the likelihood of regulatory approval and commercialization. Traders should monitor upcoming data presentations and regulatory submissions, as tozorakimab could become a key growth driver in AstraZeneca's respiratory portfolio.
Price Chart
Executive Summary
AstraZeneca announced positive high-level results from the Phase III MIRANDA trial, showing that tozorakimab significantly reduced moderate-to-severe COPD exacerbations. This marks the third successful pivotal trial for the drug, reinforcing its potential as a first-in-class IL-33-targeting biologic.
Key Facts
- Tozorakimab met the primary endpoint in the Phase III MIRANDA trial, demonstrating a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations.
- This is the third positive pivotal Phase III trial for tozorakimab, following prior successes in the OBERON and TITANIA trials.
- The MIRANDA trial evaluated a biweekly dosing regimen, expanding on previous monthly dosing data.
- Tozorakimab was generally well tolerated with a safety profile consistent with prior trials.
- The drug is being studied in additional indications, including severe viral lower respiratory tract disease and asthma.
Financial Impact
Potential for significant future revenue if approved, given COPD affects nearly 400 million people globally and current therapies fail to prevent exacerbations in over 50% of patients.
Risk Factors
- Regulatory approval is not guaranteed despite positive trial results.
- Competition from other biologics and emerging therapies in COPD could limit market penetration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003703 |
| Document: 0001654954-26-003703-index-headers.html | 0001654954-26-003703 |
| Document: 0001654954-26-003703-index.html | 0001654954-26-003703 |
| Document: 0001654954-26-003703.txt | 0001654954-26-003703 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access